Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Rivaroxaban vs Xarelto in Healthy Fasting Males
NCT04753489Phase 1Unknown
- Sponsor
- Pharmtechnology
- Start
- Feb 2021
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rivaroxaban in venous thromboembolism (VTE) (2 arms), sponsored by Pharmtechnology. Primary endpoints: Maximum Plasma Concentration and Area Under the Concentration-Time Curve from Time Zero to Last Quantifiable Concentration. Status: unknown.
02
Drugs
rivaroxaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT04753489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04753489.